How Investors are Trading the Coronavirus Outbreak

The coronavirus has gotten way out of hand.

Earlier this week, nearly 3,000 people were infected around the world. More than 81 people have now died. Chinese hospitals have been “overwhelmed.” Public transportation is being closed down to prevent the spread. Lunar New Year celebrations have been canceled.

However, it may be far worse than what’s being reported.

A nurse in Wuhan says that “close to 90,000 people in China have the disease,” far more than what’s being reported, as noted by the New York Post.

Cases have now been spotted in Hong Kong, Macau, Taipei, Thailand, Vietnam, South Korea, Singapore, Malaysia, Japan, Australia, France and the United States. Nepal has confirmed one case. Cambodia confirmed its first case, too.

In the U.S., the CDC just confirmed the fifth case in Arizona.

Still, the “CDC believes the immediate risk to the U.S. public is low at this time, but the situation is evolving rapidly,” Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases said, as quoted by CNBC, adding that there is likely to be more cases in coming days. “We have our best people working on this problem.”

As the issue grows worse, some of the top stocks to consider are:

Alpha Pro Tech (APT), which manufacturers masks and protective clothing, has seen its share price rocket from $3.60 to $7.75 in recent days.

![APT Stock Chart](https://chart.example.com/apt.png)

Inovio Pharmaceuticals (INO) is also still gaining traction after receiving a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the coronavirus. Maxim Group analysts reiterated a buy rating on the stock with a near-term price target of $6. INO stock has run from $4.3 to $5.44.
Biocryst Pharmaceuticals (BCRX) is evaluating galidesivir that could potentially treat the coronavirus. Shares of BCRX have run slightly from $2.82 to $3.11 so far.